A drug that stimulates granulocyte rostock blood for cytostatic mielodepressii


(57) Abstract:

The invention relates to medicine, specifically to Hematology, and can be used for pharmacological correction of disorders in the blood system under cytostatic mielodepressii. To do this, use dexamethasone as a means of stimulating granulocyte Rostock blood for cytostatic mielodepressii. The tool has a sufficiently high efficiency and less pronounced side effects. table 1.

The invention relates to medicine, specifically to Hematology, and can be used for pharmacological correction of disorders in the blood system under cytostatic mielodepressii.

Currently in experiment and clinic with the purpose of correction of Hypo - and aplastic state hematopoiesis, developing in the process of chemotherapy with cytotoxic drugs, use of various pharmacological agents, such as zymosan, b vitamins, Siberian ginseng, methyluracil, extract of Golden root, splenin, derivatives of nucleic acids, purine bases, mononucleotides, immunomodulators (1), digidroergotamin (2), pentamin (3), etc.

However, these drugs are not enough GPS receiver positions most promising for clinical application of drugs, created on the basis of endogenous regulators of haematopoiesis (colony-stimulating factors, interleukins, erythropoietin), but their use is also limited due to the development of side effects (5).

Mielodeprescia is one of the pathological syndromes that arise in the assignment of cytostatics and limiting significantly the duration of chemotherapy (6).

The task of the invention is the expansion of the means of stimulating granulocyte Rostock blood for cytostatic mielodepressii with high efficiency and less pronounced side effects.

This object is achieved in that as a drug that stimulates granulocyte Rostock blood for cytostatic mielodepressii use dexamethasone.

New in the present invention is that as a drug that stimulates granulocyte Rostock blood for cytostatic mielodepressii use dexamethasone.

These distinctive characteristics are not found by the authors studied in the literature and do not follow explicitly DK blood for cytostatic mielodepressii, not found. Dexamethasone is a synthetic glucocorticoid, and the closest natural glucocorticoids such property not described (7).

As shown by experimental studies, this drug can be used in medical practice to stimulate granulocyte Rostock blood for cytostatic mielodepressii.

Thus, this solution meets the criteria of the invention: "novelty", "inventive step", "industrial application". Dexamethasone is a synthetic analog of cortisone and hydrocortisone. A characteristic feature of the chemical structure is the presence in the molecule of the fluorine atom.

On the effects on the body similar to other corticosteroids, but more active than the natural. Dexamethasone has a strong anti-inflammatory and antiallergic effect.

The main indications for use of dexamethasone are collagenosis, rheumatism, rheumatoid arthritis, bronchial asthma, acute lymphoblastic and myeloblastic leukemia, infectious mononucleosis, neurodermatitis, eczema and other skin diseases, various allergic diseases, etc., In seperating and others). Immunosuppressive effect of dexamethasone can be used in the transplantation of organs and tissues to suppress rejection reactions, and various autoimmune diseases (8).

The dexamethasone (as in synthetic glucocorticosteroid) less pronounced some side effects (especially associated with sodium and water retention in the body) due to their smaller compared to natural corticosteroids mineralcorticoid action. Dexamethasone is used in edematous States, psychostimulation, hypercalcemia, predisposition to diseases of the stomach, Allergy to steroids. It should be noted also that this drug is widely used in Oncology in schema therapy of various tumors (9).

The use of dexamethasone for a new appointment was made possible thanks to the identified new property.

We first showed that the introduction of dexamethasone stimulates regeneration processes granulocyte Rostock blood for cytostatic mielodepressii caused by the use of cytostatics.

Property of dexamethasone to stimulate granoulozitopoez on the background of cytostatic mielodepressii caused by cites 0.05 mg/kg simultaneously with the introduction of the cytostatic agent in 1/2 of the maximum tolerated dose (MTD) has a stimulating effect mainly on granoulozitopoez.

The experiment was conducted on 122 mice CBA weighing 18-20, Animals were injected once intraperitoneally with 5-FU in 1/2 MTD (114 mg/kg).

Simultaneously administered dexamethasone intramuscularly (within three days) at a dose of 0.05 mg/kg / day. The control group mice after cytostatic were treated with equivalent volume of solvent (saline, 0.1 ml). Animals were scored at 6-10 days after the administration of cytostatic method of fracture of the spine in the cervical spine under ether anesthesia. Determined the total number of myelokaryocytes (COC) in the bone marrow in the hip. On bone marrow smears were counted myelogram 400 cells.

The performed research has shown that a single injection of 5-FU (cytostatica from the group of antimetabolites - analogues of pyrimidine components of nucleic acids) has led to severe hypoplasia of bone marrow hematopoiesis in 6 days from the beginning of exposure. At this moment there was a minimal value JCC, comprising 13.1% of the benchmarks. Inhibition processes granulocytopoiesis was accompanied by a decrease in the content in the bone marrow immature and Mature neutrophilic granulocytes (10,5% and 0.8%, respectively, compared to intact animals). By the end of nabla blood.

The purpose synthetic glucocorticoid dexamethasone mice simultaneously with 5-FU resulted in a pronounced stimulating effect on the pace of recovery granulocyte Rostock blood (table. 1). So, 6.9 days experiment VBEs in the bone marrow of mice treated with dexamethasone, significantly exceeded (more than 2 and 1.5 times, respectively) values observed for control animals.

Analysis of myelogram showed that the increase in VBEs is mainly due to the statistically significant increase in bone marrow content immature neutrophilic granulocytes in 6 days (5 times) and 9 days (more than 2-fold) compared with cytostatic, while for 9 days this indicator reached the original value. In addition, there has been an acceleration in the pace of recovery in the bone marrow content of Mature forms of neutrophilic granulocytes 6 (13 times compared to 5-FU), 9 days of the experiment (2 times) and eosinophils (7, 10 days) (table. 1).

The advantages of using dexamethasone as a stimulant granulocyte Rostock blood for cytostatic mielodepressii is that dexamethasone scheme introduction is applied simultaneously with the cytostatic agent that is more in the in which it provides the above-mentioned effect, that helps to reduce side effects.

Thus, the data presented clearly indicate the presence of synthetic glucocorticoid dexamethasone ability to stimulate granulocyte Rostock blood for cytostatic mielodepressii.


1. Mashkovsky M. D. Medicines.- M, Medicine, 1988,, 1 - n-248-251; so 2 - S. 17-24.

2. Patent N 2063751, B. I. N 20, 1996

3. Patent N 2083201, B. I. N 19, 1996

4. Pashinsky Century BC, Yaremenko, the Kronstadt problems of cancer pharmacotherapy. - Tomsk, 1983, c. 77-79.

5. Goldberg E. D., Digi A. M., Zhdanov Century Century Role gemopoeticescoe microenvironment in the regulation of blood when the cytotoxic myelodepression. - Tomsk: STT, 1999, c. 13-14; 86-87.

6. The Gershanovich M L. Complications of chemotherapy and hormonal therapy of malignant tumors. - M.: Medicine, 1982. - S. 120-124.

7. Goldberg E. D. , Digi A. M., Agafonov Century. And. and other Principles create medicines - blood stimulant of natural origin // Exp. and clinically. pharmacology. - 1995. - N 1 - c. 3

8. Mashkovsky M. D. Medicines. - Vilnius, 1993,, 1 - n-499.

9. Hormone therapy /Per. s nem. R. M. P. the solid fuel means, stimulating granulocyte Rostock blood for cytostatic mielodepressii.


Same patents:

The invention relates to the field of medicine and is suitable for the treatment of rheumatism, rheumatic inflammatory diseases, diseases of Edison, acute insufficiency of the adrenal cortex, bronchial asthma, acute and chronic allergic diseases, hepatitis, hepatic coma, hypoglycemic conditions, diseases of the kidneys, the blood, skin and eye diseases, systemic diseases of connective tissue

FIELD: medicine, oncology.

SUBSTANCE: invention relates to a method for treatment of chronic lympholeukosis. Method involves intravenous drop and jet administration of antitumor chemopreparations and carrying out the autochemotherapy. At the 1-st and 8-th day of treatment cyclophosphan in the dose 750 mg/m2, vincristine in the dose 1.4 mg/m2 and doxorubicin in the dose 30 mg/m2 incubated with 200 ml of autoblood are administrated to patients. From the 1-st to 14-th day of treatment prednisolone is used every day in the therapeutic dose. The treatment course is repeated in 30-35 days depending on blood indices and patient state. The total treatment of courses is 4-5. Method provides reducing cardiotoxicity of doxorubicin and cumulative toxicity of chemopreparations that allows carrying out administration of antitumor chemopreparations in the full volume to patients of elderly age groups.

EFFECT: improved method for treatment.

1 ex

FIELD: medicine, oncohematology.

SUBSTANCE: the present innovation deals with treating elderly patients with chronic lympholeukosis accompanied with cardiovascular failure. The method deals with applying chemopreparations and cytoprotector. Moreover, 1 wk before the onset of chemotherapeutic therapy one should prescribe preductal at the dosage of 105 mg daily. At this background one should sample blood out of elbow vein at the volume of 200 ml into a vial with glugicir to centrifuge it, isolate plasma, divide into two portions, add into the 1st vial - cyclophosphan 600-800 mg/sq. m, vincristin 1.4 mg/sq. m, into the 2nd vial - adriamycin 50 mg/sq. m to be incubated for 30 min at 37 C and intravenously injected by drops for patients. Simultaneously, the intake of prednisolone should be prescribed at the dosage of 60 mg/sq. m since the 1st d and during the next 5 d and preductal at the dosage of 105 mg daily during a week, and then 2 wk more at the dosage of 60 mg daily. All the procedures should be repeated in above-mentioned sequence 4-6 times. The method enables to decrease toxic manifestations of chemotherapy while applying adequate dosages of cytostatics, anthracycline antibiotics, among them, at no great manifestations of their toxicity due to preductal's cardioprotective action.

EFFECT: higher efficiency of therapy.

1 ex, 5 tbl

FIELD: medicine, neurology.

SUBSTANCE: method involves intravenous administration of autolymphocytes treated with an immunomodulating agent by extracorporal method using cycloferon (250 mg) as an immunomodulating agent. Simultaneously, the following medicinal mixture comprising lidocaine, 100 mg; lidazum, 32 U; dexamethasone, 4 mg; leukinferon, 10 000 U; 40% glucose solution, 4 ml is administrated into interspinal ligaments of spinal column at levels corresponding to thoracal and lumbar enlargements of the spinal cord. The procedure is repeated three times with interval for 48-72 h. Method provides enhancing the effectiveness of lymphostimulation and immunomodulation in cerebrospinal sclerosis. Invention can be used for lymphostimulation and immunomodulation in cerebrospinal sclerosis.

EFFECT: improved method for treatment.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves applying napkin impregnated with medicament to an injured articulation area. The medicament contains hydrocortisone acetate in the amount of 0.4mg/cm2, dimexide - 1.4 mg/cm2 and sodium alginate - 4.1 mg/cm2. The napkins are applied to internal and external side of the articulation for 6 days, changing them in three days.

EFFECT: accelerated treatment course.

FIELD: medicine, otorhinolaryngology.

SUBSTANCE: one should treat deformation in laryngeal and tracheal lumen due to excessive growth of granulation tissue in the sites of their lesions. One should introduce hormonal preparations, moreover, one should apply Diprosan as a hormonal preparation injected once intramucosally at 0.1 ml/sq. cm of granulation tissue, but not more than 0.3 ml.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves probing and rinsing lacrimal canaliculus. Working nozzle of YAG laser is additionally introduced into lacrimal canaliculus to reach medial wall of the lacrimal sac. The working nozzle of laser is taken away from the medial lacrimal sac wall in the reverse direction by 2 mm. Laser radiation treatment is applied in constant wave mode (CW) with power of 2.5 W during 5 s in smoothly moving laser working end from the lacrimal canaliculus. The lacrimal canaliculus is washed with corticosteroids.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine.

SUBSTANCE: the present innovation includes polychemotherapy and radiation therapy. Moreover, polychemotherapy should be carried out by the following scheme: on the 1st and the 8th d of the first and the third courses it is necessary to introduce doxorubicin, cyclophosphan, vincristine, and since the 1st to the 14th d - procarbazine and prednisolone; moreover, on the 1st and the 8th d of the second and the fourth courses one should introduce doxorubicin, bleomycin, vinblastine, dacarbazine. The method enables to decrease the quantity of late therapeutic complications, improves the results of relapse-free, total tumor-specific survival rate and decreases the number of polychemotherapeutic cycles.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, dermatology.

SUBSTANCE: it is suggested to apply quingamin in combination with prednisolone. The latter should be prescribed at its average daily dosages, and quingamin daily dosage should be increased for 120-130 mg every 9-11 d beginning from 120-130 mg to reach 450-500 mg/d. Moreover, course dosage of quingamin corresponds to 15-18 mg. The method decreases toxic reactions to quingamin introduction.

EFFECT: higher efficiency of therapy.

1 cl, 1 ex

FIELD: medicine.

SUBSTANCE: by the first variant, one should widen lacrimal point, pass with the probe through inferior lacrimal canaliculus up to the rest into the bone followed by visualization of nasal cavity with endoscope, control for light guide's position should be performed due to diaphanoscopic X-raying via the bone. Burning through osseous tissue of lateral wall in nasal cavity should be fulfilled with laser radiation by developing anastomosis between lacrimal sac and nasal cavity till visualization of light guide in nasal tract. Moreover, lateral wall of nasal cavity should be burned through with a solid-state Nd YAG laser at wave length being 1.44 mcm, impulse energy of 300-440 mJ, impulse frequency 10-20 Hz, impulse duration of 50-150 mcsec. Time for osseous impact corresponds to 0.4-4 min. Intubation of developed anastomosis should be carried out through inferior lacrimal point by withdrawing into nasal cavity with drainage out of silicone as a hollow tube. By the second variant, one should perform visualization of nasal cavity with endoscope followed by burning through bony tissue of lateral wall in nasal cavity with laser radiation. Moreover, light guide's fiber should be applied out of nasal cavity. Burning through should be performed by contact being 3 mm to the front against concha nasalis media in projection of lacrimal fossa with a solid-state Nd YAG laser at wave length being 1.44 mcm at impulse energy of 300-350 mJ, impulse frequency of 10-12 Hz, impulse duration of 50-150 mcsec, time for impact is 0.4-4 min. Then comes passing acutely through inferior lacrimal canaliculus till probe's appearance in developed anastomosis. Then one should fulfill intubation of developed anastomosis through inferior lacrimal point at withdrawing into nasal cavity with drainage out of silicone as a hollow tube. The method enables to achieve permeability of tear-secretion tract at low traumatism and high efficiency in postoperative period at no relapses on closing the anastomosis developed between lacrimal sac and nasal cavity.

EFFECT: higher efficiency of therapy.

2 cl, 2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: treatment involves using the injection solution based on water-soluble prednisolon formulation containing sodium salt and accessory additive. Prednisolon sodium phosphate is used as prednisolon water-soluble formulation, and anhydrous sodium hydrogen phosphate and sodium dihydrogen phosphate dihydrate taken in the ratio = (1.375-1.5):1, respectively, are used as sodium salt, and propylene glycol is used as an additional additive in the following ratio of components, wt.-%: prednisolon sodium phosphate (as measured for prednisolon), 2.5-3.5; anhydrous sodium hydrogen phosphate, 0.045-0.055; sodium dihydrogen phosphate dihydrate, 0.03-0.04; propylene glycol, 12-17, and injection water, the balance, up to 100%. Invention can be used in producing hormonal preparation prednisolon in injection formulation for treatment of rheumatism, infectious nonspecific polyarthritis, bronchial asthma, leukemia and other diseases. Invention provides enhancing stability of prednisolon-containing solution and prolonged storage time.

EFFECT: improved and valuable properties of solution.

3 tbl, 2 ex